Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: A report from the Children'S Oncology Group

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 1, 2012, Pages

  Salzer, Wanda L ^a   Winick, Naomi J ^b   Wacker, Pierre ^c   Lu, Xiaomin ^d   Devidas, Meenakshi ^e   Shuster, Jonathan J ^e   Mahoney, Donald H ^f   Lauer, Stephen J ^g   Camitta, Bruce M ^h  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Clinical and Health Psychology   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

childhood acute lymphoblastic leukemia; methotrexate metabolism; red blood cell; red blood cell methotrexate and folate

Indexed keywords

FOLIC ACID; FOLINIC ACID; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AFRICAN AMERICAN; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CHILD; CHILDHOOD LEUKEMIA; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TREATMENT FAILURE; ERYTHROCYTE; EUROPEAN AMERICAN; FEMALE; HIGH RISK PATIENT; HISPANIC; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; STEADY STATE; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; ERYTHROCYTES; FEMALE; FOLIC ACID; HUMANS; INFANT; MALE; METHOTREXATE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84855460266     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31820ee239     Document Type: Article

References (35)

1. Perrin JC, Mauer AM, Sterling TD. Intravenous methotrexate (amethopterin) therapy in the treatment of acute leukemia. Pediatrics. 1963;31:833-839.
2. Frei E III, Freireich EJ, Gehan E, et al. Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood. 1961;18:431-454.
3. Schrøder H, Clausen N, Ostergaard E, et al. Pharmacokinetics of erythrocyte methotrexate in children with acute lympho-blastic leukemia during maintenance treatment. Cancer Che-mother Pharmacol. 1986;16:190-193. (Pubitemid 16155993)
4. Graham ML, Shuster JJ, Kamen BA, et al. Red blood cell methotrexate and folate levels in children with acute lympho-blastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol. 1992;31: 217-222.
5. Graham ML, Shuster JJ, Kamen BA, et al. Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study. Clin Cancer Res. 1996;2: 331-337.
6. Cole PD, Zebala JA, Alcaraz MJ, et al. Pharmacodynamic properties of methotrexate and aminotrexate during weekly therapy. Cancer Chemother Pharmacol. 2006;57:826-834.
7. Vijayanathan V, Smith AK, Zebala JA, et al. High-performance liquid chromatography separation of aminopterin-polyglutamates within red blood cells of children treated for acute lymphoblastic leukemia. Transl Res. 2007;150:367-373. (Pubitemid 350101441)
8. Kamen BA, Holcenberg JS, Turo K, et al. Methotrexate and folate content of erythrocytes in patients receiving oral versus intramuscular therapy with methotrexate. J Pediatr. 1984;104: 131-133. (Pubitemid 14178477)
9. Kamen BA, Nylen PA, Camitta BM, et al. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol. 1981;49:355-360. (Pubitemid 11027829)
10. Balis FM, Holcenberg JS, Poplack DG, et al. Pharmacoki-netics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint Children's Cancer Group and Pediatric Oncology branch study. Blood. 1998;92:3569-3577. (Pubitemid 28525181)
11. Evans WE, Abromowitch M, Crom WR, et al. Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia. NCI Monogr. 1987;5:81-85. (Pubitemid 18000401)
12. Seidel H, Nygaard R, Moe PJ, et al. On the prognostic value of systemic methotrexate clearance in childhood acute lympho-cytic leukemia. Leuk Res. 1997;21:429-434. (Pubitemid 27308238)
13. Camitta B, Mahoney D, Leventhal B, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1994;12: 1383-1389.
14. da Costa M, Iqbal MP. The transport and accumulation of methotrexate in human erythrocytes. Cancer. 1981;48: 2427-2432. (Pubitemid 12228004)
15. Baugh CM, Krumdieck CL, Nair MG. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun. 1973;52:27-34.
16. Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy-a Pediatric Oncology Group study. J Clin Oncol. 1998;16:1712-1722.
17. Lauer SJ, Shuster JJ, Mahoney DH Jr, et al. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. Leukemia. 2001;15: 1038-1045. (Pubitemid 32717272)
18. Kamen BA, Caston JD. Direct radiochemical assay for serum folate: competition between 3H-folic acid and 5-methyltetra-hydrofolic acid for a folate binder. J Lab Clin Med. 1974;83: 164-174.
19. Kamen BA, Takach PL, Vatev R, et al. A rapid, radio-chemical-ligand binding assay for methotrexate. Anal Biochem. 1976;70:54-63.
20. Kamen BA, Caston JD. Properties of a folate binding protein (FBP) isolated from porcine kidney. Biochem Pharmacol. 1986;35:2323-2329. (Pubitemid 16041951)
21. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, Inc; 1980:14.
22. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187-220.
23. Patrick J, Thomas L, Margaret S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337-344.
24. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006;108:441-451. (Pubitemid 44061340)
25. Keefe DA, Capizzi RL, Rudnick SA. Methotrexate cytotoxi-city for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability. Cancer Res. 1982;42:1641-1645. (Pubitemid 12103350)
26. Borsi JD, Moe PJ. A comparative study on the pharmacoki-netics of methotrexate in a dose range of 0.5 g to 33.6 g/m#sup#2#/sup# in children with acute lymphoblastic leukemia. Cancer. 1987;60:5-13. (Pubitemid 17083543)
27. Rodman JH, Sunderland M, Kavanagh RL, et al. Pharma-cokinetics of continuous infusion of methotrexate and tenipo-side in pediatric cancer patients. Cancer Res. 1990;50: 4267-4271. (Pubitemid 20225662)
28. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 1986;314: 471-477.
29. Evans WE, Schell MJ, Pui CH. MTX clearance is more important for intermediate-risk ALL. J Clin Oncol. 1990;8: 1115-1116. (Pubitemid 20200201)
30. Sirotnak FM, Donsbach RC, Moccio DM, et al. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model. Cancer Res. 1976;36:4679-4686.
31. Sirotnak FM, Moccio DM, Dorick DM. Optimization of highdose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res. 1978;38:345-353. (Pubitemid 8283955)
32. Skarby TVC, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia. 2006;20:1955-1962. (Pubitemid 44614884)
33. Sterba J, Dusek L, Demlova R, et al. Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: "folate overrescue" concept revisited. Clin Chem. 2006;52:692-700.
34. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010;116: 4874-4884.
35. Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA. 2009;301:393-403.